



Contact: Yie-Hwa Chang
Location: 5445 Highland Park Drive
Email: yiechang@mediomics.com
Tel: 314-971-3026
Website: www.mediomics.com



U. S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health



National Institutes of Health Commercialization Assistance Program
(NIH-CAP)

Company Profile

Industry Sector: Life Science

Company Overview:

Mediomics is focusing on developing innovative biosensors, homogeneous bioassays and novel high affinity reagents.

Target Market(s):

Contract manufacturing organizations (CMOs), Contract research organizations (CROs), Biotech companies, Biopharmaceutical companies and Companies developing single use bioreactors.

Key Value Drivers

Technology*:

Molecular PINCER, a platform technology that allows Mediomics to develop a series of homogeneous bioassays and point of care testing biosensors.

Competitive Advantage:

Automated on-line analysis which will reduce cost, reduce chance of contamination and improve productivity.

Plan & Strategy:

1. We will use the phase II fund to develop a prototype of the automated on-line biosensor and validate the performance of the biosensor with various bioassays by third parties.
2. We will raise fund to manufacture 300 biosensor systems and strengthen Mediomics' operation and marketing team.

Management

Leadership:

- ❖ Yie-Hwa Chang, Ph.D., President and CEO
- ❖ Margaret Meng, Chief Administrative Officer
- ❖ Preston Keller, Business Development and Marketing
- ❖ Edward Bayham, Finance

Scientific Advisory Board:

- ❖ Tomasz Heyduk, Professor of Biochemistry and Molecular Biology, St. Louis University Doisy Research Center.
- ❖ DaRen Chen, Ph.D., Flord Gottward Chair Professor, School of Engineering, Virginia Commonwealth University.
- ❖ David Smoller, Ph.D., Former CSO of Sigma Aldrich.

Product Pipeline

1. Automated on-line biosensor system.
2. Companion bioassays to monitor the titer of biologics and quality of biologics.

